tbuckley/cabot-search huggingface dataset:
Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma
Authors: Olivier Hermine, Ambroise Marçais, Thiago Maciel, J Bagbor, Darius Jagielski, Nadine Holtermann, Elena Martinez de Merlo, Douglas H. Thamm, Patrice Dubreuil, Alain Moussy
Journal: Blood (2015)
Hemophagocytic Lymphohistiocytosis Is Caused by Engulfment of Hematopoietic Stem Cells by Macrophages Through Stem Cell-Specific Suppression of CD47 Under Influence of Cytokine Deregulation
Authors: Takuro Kuriyama, Katsuto Takenaka, Kentaro Kohno, Goichi Yoshimoto, Junji Kishimoto, Yasunobu Abe, Toshihiro Miyamoto, Koichi Akashi
Journal: Blood (2011)
Bayesian Network Meta-Analysis (NMA): Safety of Bortezomib, Thalidomide or Lenalidomide Containing Regimens for Transplant Ineligible Multiple Myeloma (MM) Patients
Authors: Toshihisa Satta, Norihiro Yamaguchi, Adriana Malone, James Talcott, Ajai Chari
Journal: Blood (2015)
Abnormal PI 3-Kinase Activity Due to Increased Lyn with Decreased PTEN and Absent SHIP in Bone Marrow Cells from Patients with Myelodysplastic Syndromes.
Authors: Daniel W. Lee, Quan-Sheng Zhu, Sonali Rudra, Elizabeth J. Shpall, Steven Kornblau, Seth J. Corey
Journal: Blood (2005)
Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).
Authors: Parinda A. Mehta, Stella M. Davies, Ashish Kumar, Meenakshi Devidas, Susan Lee, Tiffany Wilke, James Elliott, Joyce Villanueva, Jeanette Pullen, Yetnayet Zewge, Alexandra H. Filipovich
Journal: Blood (2005)
Cdx4 Differs from Cdx2 in Its Oncogenic Potential and Its Regulation of Hox Gene Expression in the Murine Bone Marrow Transplantation Model.
Authors: Silvia Thoene, Vijay P.S. Rawat, Vegi M. Naidu, Wolfgang Hiddemann, Michaela Feuring-Buske, Christian Buske
Journal: Blood (2008)
Lenalidomide after Allogeneic Stem Cell Transplantation in Multiple Myeloma.
Authors: Friederike Lehmann, El-Cheikh Jean, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Lars Petersen, Ulrike Bacher, Axel R. Zander, Didier Blaise, Mohamad Mohty, Kroeger Nikolaus
Journal: Blood (2007)
Human SIRPA Polymorphism Modulates Macrophage-Mediated Suppression of Human Hematopoiesis
Authors: Takuro Kuriyama, Katsuto Takenaka, Takashi Kumano, Seido Oku, Shingo Urata, Koji Nagafuji, John E. Dick, Jayne S Danska, Koichi Akashi
Journal: Blood (2008)
Immature Platelet Fraction As a Measure of Thrombocytopenia in Trauma Patients and Its Cut off Value with Severity of Thrombocytopenia
Authors: Bhaumik Arvindkumar Shah, Arulselvi Subramanium, Hara prasad Pati, Subhadra Sharma, Deepak Agrawal, Rajesh Ahuja, Asok Kumar Mukhopadhyay
Journal: Blood (2011)
The effect of PcrV antibody to multidrug resistant pseudomonas aeruginosa induced cytoxicity
Authors: Qin Wang, Huayin Li, Yuanlin Song, Chunxue Bai
Journal: European Respiratory Journal (2012)

Pseudomonas aeruginosa is an important nosocomial pathogens. Mab166, a murine monoclonal antibody against PcrV, has demonstrated efficacy against P. aeruginosa infection. However, evidences mainly come from laboratory strains. The expression level of type III secretion system of multidrug resistant strains is still unknown, and whether Mab166 can protect multidrug resistant strains induced infection is also unknown. So, we conduct a study to solve this problem.

We collected 47 strains including 24 mutlisdrug resistant strains, then analyze the expression of type III secretion system in two groups, we found that there are no significant differences between two groups, which was shown in figure 1.

![Figure][1] 



The protective effect of Mab166 against each strain was determined using BEAS-2B cell cytotoxicity assay, we found that Mab166 can reduced P. aeruginsa induced cytoxicity, which was shown in figure 2.

![Figure][1] 



These data suggest that the type III secretion expression level in multidrug reisitant strains is comparable to susceptible strains, anti-PcrV antibody can protect multidrug resistant P. aeruginsa induced cytoxicity, so we conclude that PcrV can be a treating target.

 [1]: pending:yes
Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkin’s Lymphoma.
Authors: Stefan Hohaus, Manuela Giachelia, Annalaura Di Febo, Maurizio Martini, Giuseppina Massini, Barbara Vanata, Giovanna Mansueto, Francesco Guidi, Luigi M. Larocca, Maria Teresa Voso, Giuseppe Leone
Journal: Blood (2005)
Double Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Results In Successful Engraftment of Bone Marrow From Both Donors without Graft Versus Host or Graft Versus Graft Effects.
Authors: Chandra Biswas, Daniel Rittenberg, Xiaoling Luo, Christopher Sauter, Dolores Grosso, Neal Flomenberg, Onder Alpdogan
Journal: Blood (2010)
Whole-Exome Analysis of Autoimmune Lymphoproliferative Syndrome-like Diseases
Authors: Masatoshi Takagi, Kohsuke Imai, Jinhua Piao, Motoy Yamashita, Akihiro Hoshino, Tsubasa Okano, Hirokazu Kanegane, Hideki Muramatsu, Yusuke Okuno, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Satoru Miyano, Kenichi Yoshida, Hiroo Ueno, Seishi Ogawa, Yasuhide Hayashi, Seiji Kojima, Tomohiro Morio
Journal: Blood (2015)
Irradiation-Induced Growth Hormone Neurosecretory Disfunction In ALL Patients
Authors: Gulay Biceroglu, Teoman Akcay, Gonul Aydogan, Arzu Akcay, Ferhan Akici, Deniz Tugcu, Zafer Salcioglu, Hulya Sayilan, Nuray Ayaz
Journal: Blood (2010)
Individualised advice on type 2 diabetes is no better for changing behaviour, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

Giving healthy middle aged people individualised information based on their genetic risk of developing type 2 diabetes or their phenotypic factors such as body mass index has no greater effect on physical activity or other health behaviours than standard information about the condition, a UK randomised study has found.1

A growing number of direct-to-consumer genetic tests to calculate the risk of type 2 diabetes aim to motivate people to change their health related behaviour more than with standard lifestyle advice. But research evidence on the effect …
Evaluation of the Interest of BRAF –V600E Mutation Detection By Arms-qPCR in Hairy Cell Leukemia Diagnosis and Treatment Monitoring
Authors: Ouda Ghoual, Stéphanie Jouve, Véronique Salaun, Stéphane Cheze, Michele Malet, Xavier Troussard, Dina Istasi
Journal: Blood (2014)
Effectiveness of Reduced Toxicity Conditioning Regimen with Intravenous Busulfan Plus Pentostatin (BUPENT) in Patients Older Than 50 Years with Advanced Hematologic Malignancies.
Authors: Tulio E. Rodriguez, Mala Parthasarathy, Scott E. Smith, David H. Vesole, Zachary M. Earley, Aaron T. Gerds, Amir A. Toor, Patrick J. Stiff
Journal: Blood (2009)
Abstract 1875: Development of a dietary inflammation score and its association with incident, sporadic colorectal adenoma
Authors: Ashley C. Holmes, Roberd M. Bostick
Journal: Cancer Research (2015)

Abstract It is now well established that inflammation is linked to colorectal carcinogenesis and other chronic diseases. The ability to characterize specific dietary and lifestyle components as having pro- or anti-inflammatory effects is a promising area of cancer prevention. We developed a “dietary inflammation score” based on associations of independent dietary components with plasma C-reactive protein (CRP) in the combined Markers of Adenomatous Polyps (MAPs) case-control studies, and investigated the association of the score with incident, sporadic colorectal adenoma in the same population. First, we excluded individuals who regularly took non-steroidal anti-inflammatory drugs (NSAIDs) and multivitamins, and among those remaining (n = 369) calculated the multivariable-adjusted associations of the individual dietary components with CRP, used the strengths of associations as weights, and summed the weighted dietary components to create an overall summary dietary inflammation score. Food components were included in the score based on biological plausibility and previous literature, and included four categories of meat, nuts, pepper, coffee, tea, high- and low-fat dairy products, refined and whole grains, and twelve botanical categories. The crude odds ratio (OR) for the association of the highest dietary score tertile with log-transformed CRP was 1.92 (95% confidence interval [CI]: 1.13, 3.27); after adjusting for age, sex, total energy intake, and lifestyle inflammation score category, the OR was 1.89 (95% CI: 1.06, 3.36). The association tended to be stronger among older individuals, males, and adenoma cases. The overall score was more strongly associated with CRP than was any individual dietary component. Next, to assess the association of the dietary inflammation score with adenomas, we used the entire MAPs population (n = 188 cases and 325 controls)– including the regular NSAID and multivitamin users. The crude OR for the association of the highest dietary score tertile with incident adenoma was 1.30 (95% CI: 0.84, 2.02), an association that tended to be stronger among men and those who regularly took aspirin or other NSAIDs. Multivariable adjustment did not appreciably change these estimates. The results from this pilot study suggest that diet may contribute to systemic levels of inflammation, and support further investigation of a dietary inflammation score with colorectal neoplasms and other chronic diseases in larger studies. Citation Format: Ashley C. Holmes, Roberd M. Bostick. Development of a dietary inflammation score and its association with incident, sporadic colorectal adenoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1875. doi:10.1158/1538-7445.AM2015-1875
Upper-Airway Collapsibility and Loop Gain Predict the Response to Oral Appliance Therapy in Patients with Obstructive Sleep Apnea
Authors: Bradley A. Edwards, Christopher Andara, Shane Landry, Scott A. Sands, Simon A. Joosten, Robert L. Owens, David P. White, Garun S. Hamilton, Andrew Wellman
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Rationale: Oral appliances (OAs) are commonly used as an alternative treatment to continuous positive airway pressure for patients with obstructive sleep apnea (OSA). However, OAs have variable success at reducing the apnea–hypopnea index (AHI), and predicting responders is challenging. Understanding this variability may lie with the recognition that OSA is a multifactorial disorder and that OAs may affect more than just upper-airway anatomy/collapsibility.Objectives: The objectives of this study were to determine how OA alters AHI and four phenotypic traits (upper-airway anatomy/collapsibility and muscle function, loop gain, and arousal threshold), and baseline predictors of which patients gain the greatest benefit from therapy.Methods: In a randomized crossover study, 14 patients with OSA attended two sleep studies with and without their OA. Under each condition, AHI and the phenotypic traits were assessed. Multiple linear regression was used to determine independent predictors of the reduction in AHI.Measurements and Main Results: OA therapy reduced the AHI (30 ± 5 vs. 11 ± 2 events/h; P < 0.05), which was driven by improvements in upper-airway anatomy/collapsibility under passive (1.9 ± 0.7 vs. 4.7 ± 0.6 L/min; P < 0.005) and active conditions (2.4 ± 0.9 vs. 6.2 ± 0.4 L/min; P < 0.001). No changes were seen in muscle function, loop gain, or the arousal threshold. Using multivariate analysis, baseline passive upper-airway collapsibility and loop gain were independent predictors of the reduction in AHI (r2 = 0.70; P = 0.001).Conclusions: Our findings suggest that OA therapy improves the upper-airway collapsibility under passive and active conditions. Importantly, a greater response to therapy occurred in those patients with a mild anatomic compromise and a lower loop gain.
Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells
Authors: Warren Fiskus, Rekha Rao, Ramesh Balusu, Jianguo Tao, Eduardo M. Sotomayor, Peter Atadja, Kapil N. Bhalla
Journal: Blood (2010)
A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Authors: Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research (2016)

Hormone receptor-positive (HR
Time of Relapse after Initial Therapy Significantly Adds to the Prognostic Value of the IPI-R in Patients with Relapsed DLBCL Undergoing Autologous HSC Transplantation.
Authors: Luciano J. Costa, Ivana N. Micallef, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell
Journal: Blood (2007)
Presence of Comorbidities Do Not Predict Early Mortality or Survival in Older Patients (≥60 Years) with Acute Myeloid Leukemia (AML) Undergoing Intensive Induction Therapy.
Authors: Vikas Gupta, Christine Keng, Wei Xu, Joseph Brandwein, Aaron Schimmer, Andre Schuh, Karen Yee, Mark Minden, Shabbir Alibhai
Journal: Blood (2006)
Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies
Authors: Amin M Alousi, Borje S. Andersson, Rima M. Saliba, Wendeline Botnick, Gabriela Rondon, Elizabeth J. Shpall, Marcos de Lima, Uday Popat, Chitra Hosing, Partow Kebriaei, Issa Khouri, Muzaffar H. Qazilbash, Paolo Anderlini, Yago Nieto, Stefan Ciurea, Roy Jones, Richard Champlin
Journal: Blood (2010)
Gene Expression Profiling Reveals The Lymph Node Microenvironment As a Niche For BCR Engagement, NFκB Pathway Activation, and Tumor Proliferation In Mantle Cell Lymphoma
Authors: Nakhle S Saba, Delong Liu, Sarah E. M. Herman, Cliona Grant, Kieron Dunleavy, Stefania Pittaluga, Wyndham H Wilson, Adrian Wiestner
Journal: Blood (2013)
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
Authors: J Yu, L Chen, B Cui, Christina Wu, M Y Choi, Y Chen, L Zhang, L Z Rassenti, G F Widhopf II, T J Kipps
Journal: Leukemia (2016)

Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton’s tyrosine kinase (BTK) that can block BCR-signaling. However, ibrutinib cannot induce complete responses (CR) or durable remissions without continued therapy, suggesting alternative pathways also contribute to CLL growth/survival that are independent of BCR-signaling. ROR1 is a receptor for Wnt5a, which can promote activation of Rac1 to enhance CLL-cell proliferation and survival. In this study, we found that CLL cells of patients treated with ibrutinib had activated Rac1. Moreover, Wnt5a could induce Rac1 activation and enhance proliferation of CLL cells treated with ibrutinib at concentrations that were effective in completely inhibiting BTK and BCR-signaling. Wnt5a-induced Rac1 activation could be blocked by cirmtuzumab (UC-961), an anti-ROR1 mAb. We found that treatment with cirmtuzumab and ibrutinib was significantly more effective than treatment with either agent alone in clearing leukemia cells in vivo. This study indicates that cirmtuzumab may enhance the activity of ibrutinib in the treatment of patients with CLL or other ROR1+ B-cell malignancies.
Screening for Type 1 Diabetes–, Thyroid-, Gastric-, and Adrenal-Specific Humoral Autoimmunity in 529 Children and Adolescents With Celiac Disease at Diagnosis Identifies as Positive One in Every Nine Patients
Authors: Claudio Tiberti, Monica Montuori, Francesca Panimolle, Chiara M. Trovato, Caterina Anania, Francesco Valitutti, Anna R. Vestri, Andrea Lenzi, Salvatore Cucchiara, Susanna Morano
Journal: Diabetes Care (2016)

Organ-specific autoimmune disorders are often associated with celiac disease (CD) (1,2). Most studies investigated the frequency of CD humoral autoimmunity in patients at diagnosis of an organ-specific autoimmune disorder or along its course. Conversely, only two studies, dating back to the early 2000s, were aimed at determining the frequency and co-occurrence of organ-specific autoimmunity in CD patients at diagnosis (3,4). These studies reported discordant, excessively high positivities for diabetes-specific autoimmunity (12.2% and 31.6%, respectively) that may be explained by the small number of patients investigated and the use of, at least in part, outdated techniques such as islet cell autoantibody assay.

On these bases, our aim was to evaluate in a large cohort of CD patients at diagnosis the real frequency and co-occurrence of humoral immunoreactivity specific of four organ-specific autoimmune disorders known to be associated to CD, namely, type 1 diabetes (T1D), autoimmune thyroid disease (HT), autoimmune atrophic gastritis (AG), and Addison …
Eight Cases of Leukemia Treated with HLA Haploidentical Related Bone Marrow Transplantation and Chinese Herbal Medicine.
Authors: Yuhong Zhou, Rongxi Yu, Baodong Ye, Shengyun Lin, Zhiyin Zheng, Xiusu Luo, Jianping Shen, Zhiping Hu, Junfa Cheng
Journal: Blood (2006)
Avoiding Hospitalizations From Nursing Homes for Potentially Burdensome Care
Authors: Andrew B. Cohen, M. Tish Knobf, Terri R. Fried
Journal: JAMA Internal Medicine (2016)

Nursing home residents are often hospitalized for care that has the potential to be burdensome, in the sense that the risks outweigh the expected benefits.1 These hospitalizations offer little hope of improving quality of life or changing the course of illness and usually involve residents close to death who are vulnerable to iatrogenic harms. Certain facilities are more successful than others at preventing potentially burdensome hospitalizations. The reasons for their success, however, are poorly understood. We sought to explore the causes of these transfers and identify practices that help facilities avoid them.
Bortezomib Attenuates Adhesion of B Cell Precursor Acute Lymphoblastic Lleukemia Cells to Bone Marrow Mesenchymal Stromal/Stem Cells Via Regulating SPARC Expression
Authors: Masaki Iwasa, Yasuo Miura, Aya Fujishiro, Sumie Fujii, Noriko Sugino, Satoshi Yoshioka, Akihiro Tamura, Atsushi Sato, Asumi Yokota, Katsuyuki Kito, Akira Ando, Hideyo Hirai, Akifumi Takaori-Kondo, Tatsuo Ichinohe, Taira Maekawa
Journal: Blood (2015)
Agriculture and the energy-complexity spiral
Authors: Joseph A. Tainter
Journal: Behavioral and Brain Sciences (2016)

The study of cultural complexity is entwined with ancestors myths from contemporary cosmology. Gowdy & Krall expose this mythology by arguing that complexity emerged from economic changes following cultivation. There is more, however, to the development of cultural complexity. Complexity can emerge from abundant energy or from addressing societal problems, which compels still further energy production.
Day 15 Dendritic Cell Recovery Predicts Overall Survivial after Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.
Authors: Mustaqeem A. Siddiqui, Svetomir N. Markovic, Wendy K. Nevala, William Morice, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Luis Porrata
Journal: Blood (2007)
A microRNA Signature Predicts Response to Anti-CD19 Therapy (MEDI-551) in B-Cell Malignancies
Authors: Katie Streicher, Philip Brohawn, Mike Kuziora, Fernanda Pilataxi, Brandon Higgs, Kim Lehmann, Kathleen McKeever, Trishna Goswami, Ronald Herbst, Yihong Yao, Koustubh Ranade
Journal: Blood (2014)
P0897 : Efficacy of simeprevir and sofosbuvir for treatment of cirrhotic patients with genotype 1 chronic hepatitis C – a single center experience
Authors: V. Singh, T. Frederick, E.W. Holt, A.E. Wakil, J. Guy, R.B. Merriman, T.J. Davern, K.K. Yimam, C.K. Ho, T.K. Lee, S.L. Cooper
Journal: Journal of Hepatology (2015)
Minor Histocompatibility Antigen Mismatches and Graft Versus Host and Relapse in High-Resolution HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Manuel Cliquennois, Pascale Cracco, Dominique Becuwe, Julia Salleron, Françoise Dufossé, Alain Duhamel, Jean-Pierre Jouet, Jean-Paul Dessaint, Myriam Labalette, Ibrahim Yakoub-Agha
Journal: Blood (2008)
Renal Function Impairment and Outcomes of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Jonas A. de Souza, Rima Saliba, Poliana A. Patah, Gabriela Rondon, Muzaffar H. Qazilbash, Chitra Hosing, Uday Popat, Richard E. Champlin, Marcos de Lima
Journal: Blood (2006)
Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis
Authors: John M Hollingsworth, Benjamin K Canales, Mary A M Rogers, Shyam Sukumar, Phyllis Yan, Gretchen M Kuntz, Philipp Dahm
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To investigate the efficacy and safety of alpha blockers in the treatment of patients with ureteric stones. <b>Design</b>&nbsp;Systematic review and meta-analysis. <b>Data sources</b>&nbsp;Cochrane Central Register of Controlled Trials, Web of Science, Embase, LILACS, and Medline databases and scientific meeting abstracts to July 2016. <b>Review methods</b>&nbsp;Randomized controlled trials of alpha blockers compared with placebo or control for treatment of ureteric stones were eligible.<b></b>Two team members independently extracted data from each included study. The primary outcome was the proportion of patients who passed their stone. Secondary outcomes were the time to passage; the number of pain episodes; and the proportions of patients who underwent surgery, required admission to hospital, and experienced an adverse event. Pooled risk ratios and 95% confidence intervals were calculated for the primary outcome with profile likelihood random effects models. Cochrane Collaboration's tool for assessing risk of bias and the GRADE approach were used to evaluate the quality of evidence and summarize conclusions. <b>Results</b>&nbsp;55 randomized controlled trials were included. There was moderate quality evidence that alpha blockers facilitate passage of ureteric stones (risk ratio 1.49, 95% confidence interval 1.39 to 1.61). Based on a priori subgroup analysis, there seemed to be no benefit to treatment with alpha blocker among patients with smaller ureteric stones (1.19, 1.00 to 1.48). Patients with larger stones treated with an alpha blocker, however, had a 57% higher risk of stone passage compared with controls (1.57, 1.17 to 2.27). The effect of alpha blockers was independent of stone location (1.48 (1.05 to 2.10) for upper or middle stones; 1.49 (1.38 to 1.63) for lower stones). Compared with controls, patients who received alpha blockers had significantly shorter times to stone passage (mean difference −3.79 days, −4.45 to −3.14; moderate quality evidence), fewer episodes of pain (−0.74 episodes, −1.28 to −0.21; low quality evidence), lower risks of surgical intervention (risk ratio 0.44, 0.37 to 0.52; moderate quality evidence), and lower risks of admission to hospital (0.37, 0.22 to 0.64; moderate quality evidence). The risk of a serious adverse event was similar between treatment and control groups (1.49, 0.24 to 9.35; low quality evidence). <b>Conclusions</b>&nbsp;Alpha blockers seem efficacious in the treatment of patients with ureteric stones who are amenable to conservative management. The greatest benefit might be among those with larger stones. These results support current guideline recommendations advocating a role for alpha blockers in patients with ureteric stones. <b>Systematic review registration</b>&nbsp;PROSPERO registration No CRD42015024169.